BSE filing, NSE: BAJAJHCARE. Summary written from the filing by ALFA Finder's alert engine.
Bajaj Healthcare Ltd: key numbers
- Share price
- ₹313.85
- Market cap
- ₹1,057 Cr
- Revenue (annual)
- ₹611.0 Cr
- Net profit (annual)
- ₹15.77 Cr
- P/E (TTM)
- 51.2×Sector 46.5×
- Promoter holding
- 58.59%+0.00% QoQ
- FII holding
- 2.09%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bajaj Healthcare Ltd
All →Bajaj Healthcare Earnings Call Transcript: Key Takeaways
Bajaj Healthcare delivered strong H1 growth led by a 82% surge in formulations and key new specialty launches.
- Call
- Guides 15% growth
Bajaj Healthcare Results Update
Bajaj Healthcare reported Q2 FY27 revenue of ₹175.9 Crore, up 18.9% YoY. EBITDA stood at ₹32.1 Crore, reflecting a 12.2% YoY increase.
Bajaj Healthcare Q2 FY27 Results: Net Profit ₹14.1 Cr, Up 27.0% YoY
Bajaj Healthcare Ltd reported revenue from operations of ₹175.9 Cr (+18.9% YoY) and net profit of ₹14.1 Cr (+27.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹14.1 Cr · +27.0% YoY
Bajaj Healthcare Acquisition
Bajaj Healthcare received NCLT approval to acquire Genrx Pharmaceuticals Private Limited as a going concern. The entity will become a wholly owned subsidiary.
Bajaj Healthcare Merger & Restructuring Worth ₹14.67 Cr
Bajaj Healthcare Limited has executed a deed of assignment to sell its undertaking located in Dahej Industrial Area, Gujarat, for approximately Rs. 14.67 Crore.
- Value
- ₹14.67 Cr
Bajaj Healthcare Board Meeting Date
Bajaj Healthcare Limited announced a board meeting on October 17, 2026, to approve the company's un-audited financial results for the quarter and half-year ended September 30, 2026.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.